Kaveri Parker, PhD

Dr. Kaveri Parker is a forward-thinking and strategic executive with experience at the intersection of science, innovation, business, and operations. She joined Alume Biosciences in February 2025.

Prior to joining Alume Biosciences, Dr. Parker was the Chief Business Officer of Synedgen, Inc. where she oversaw commercial, strategic and business development activities for the Company’s drug and medical device assets. While at Synedgen, Dr. Parker secured both dilutive and non-dilutive funding for complex and high-risk programs and was the co-architect of a $110M contract with the Biomedical Advanced Research and Development Authority (BARDA). She also secured high-value partnerships with public and private stakeholders. She additionally serves as the strategic and commercialization lead for a national pandemic preparedness team at the Mayo Clinic. She has ongoing Strategy and Transaction Advisory roles with multiple private companies. She was previously the President and CEO of ID Genomics, a company focused on antibiotic susceptibility testing. Dr. Parker has a Ph.D. from Washington University School of Medicine in Saint Louis.